Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Point Biopharma Inc. has 2 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These actions are located within 1 distinct art unit, indicating a concentrated regulatory environment for the company's current applications. Prosecution is handled by 2 distinct examiners. This structure provides a diversified exposure to examiner perspectives within a particular art unit.
The busiest examiner for this portfolio is JONES, DAMERON LEVEST, who is responsible for 1 pending action. With the 2 pending office actions overall, the company faces a distributed examination process where no particular examiner controls all of the pending outcomes. This parity between the number of examiners and the number of actions simplifies the tracking of individual examiner tendencies. The focus on the Biotechnology & Pharmaceuticals area suggests that the company is prioritizing its core life sciences innovations in its current patent strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
| PERREIRA, MELISSA JEAN | 1 | 52.1% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18675346 | RADIOPHARMACEUTICAL TREATMENT METHODS AND USE | JONES, DAMERON LEVEST | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18675346 | RADIOPHARMACEUTICAL TREATMENT METHODS AND USE | JONES, DAMERON LEVEST | — |
| 17934450 | RADIOPHARMACEUTICAL AND METHODS | PERREIRA, MELISSA JEAN | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18675346 | RADIOPHARMACEUTICAL TREATMENT METHODS AND USE | JONES, DAMERON LEVEST | 1618 | §103§112Other | Non-Final OA | — | Pending | May 28, 2024 |
| 17934450 | RADIOPHARMACEUTICAL AND METHODS | PERREIRA, MELISSA JEAN | 1618 | §103DP | Non-Final OA | — | Pending | Sep 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPoint Biopharma Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Dameron Levest Jones has the most, with 1 of Point Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
